Omeza recently announced a partnership with Sarasota physician Dr. John Yee as a sub-investigator for their innovative Omeza® Treatment Bundle for the treatment of chronic and complicated wounds.
While product development, manufacturing, and corporate headquarters have been located in Sarasota, FL since the company’s formation in 2016, most Omeza clinical trial sites to date have been located elsewhere around the country.
With Dr. John Yee joining as a local sub-investigator, Omeza will be able to offer eligible patients in the area access to participate in this Expanded Indications Trial which will allow investigators to preliminarily evaluate the potential effectiveness of the Omeza® Treatment Bundle.
States Tom Gardner, Omeza founder and CEO, “Since our company was officially formed, we’ve regularly had inquiries from the community about participating in clinical trials. While we are excited to have studies on-going across the country, we are happy to have this local practice doing research in our backyard.”
The study, called An Open Label Pilot Study to Evaluate the Omeza® Treatment Bundle in the Management and Treatment of Chronic Cutaneous Ulcers of Multiple Etiologies will take place over a period of 12 weeks per patient.
Patient indications include partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Moh’s surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, skin tears) and draining wounds.
In December 2020, First Coast Cardio in Jacksonville became the first Florida clinical trial site for the investigation of the Omeza® Treatment Bundle as compared to standard of care (SOC) for (?) subjects with chronic venous leg ulcers or diabetic foot ulcers.
For more information contact Omeza through their professional website OmezaPro.com.